Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

This study has been completed.
Information provided by (Responsible Party):
Spectrum Pharmaceuticals, Inc Identifier:
First received: May 28, 2010
Last updated: July 20, 2016
Last verified: July 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2015
  Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)